Loading
FA
Flyte Aviation, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by JENKINS DAVID A, was filed 24 Jan 2024.
Flyte Aviation, Inc.: what insiders have been doing
Flyte Aviation, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 22 October 2025 and 22 October 2026, 2 insiders published 4 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
There has been no open-market purchase by an insider of Flyte Aviation, Inc. for at least a year. The median gap between a trade and its publication by SEC (Form 4) is 3 days. For comparison, the SEC allows two business days to file a Form 4.
Across the 2,023 companies tracked on its exchange, the median is 41 filings; at 4 filings, this issuer sits below that mark. The full history, which starts in 2018, counts 20 purchases against 28 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 819,000 USD and net income at -17.2 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
111
Thresholds
n/a
Buy Volume
€192,305
20 ops. · all time
Sell Volume
€636,925
28 ops. · all time
Who traded when
BuySaleMartin J. Colombatto1 sale
Since the insiders bought
- -93.1%Entry US$1,121.00 · Close at T+365 US$77.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.15
Analyst consensus
Income statement
RevenueUS$819k
Gross profitUS$756k92% margin
EBITDA-US$17.1M-2089% margin
Net income-US$17.2M-2098.0% margin
Valuation
P/Book0.0x
Beta0.51
Balance sheet & cash
Total debtUS$3.8M
Free Cash Flow-US$8.4M
Debt / Equity80%
Profitability & ownership
ROE-111.4%
ROA-24.1%
% insiders20.0%
% institutions0.7%
Last declaration on 8 December 2025
Declarations111 total
30,844 shares0Common StockSEC:0001437749-25-037162:1
98 shares0Common StockSEC:0001437749-25-037162:2
41 shares0Common StockSEC:0001437749-25-037173:0
12,064 shares0Common StockSEC:0001437749-25-037162:0
3 shares@ US$0.4002100.0% of flowCommon StockSEC:0001437749-25-002433:0
9,528 shares@ US$0.429538.7% of flowCommon StockSEC:0001654954-24-000874:0
Canonical exit: 21 Apr 2024 (T+90)
9,528 shares@ US$0.597624.6% of flowCommon StockSEC:0001654954-24-000874:1
Canonical exit: 22 Apr 2024 (T+90)
8,470 shares@ US$0.424415.5% of flowCommon StockSEC:0001654954-24-000790:1
Canonical exit: 18 Apr 2024 (T+90)
8,470 shares@ US$0.412233.0% of flowCommon StockSEC:0001654954-24-000790:0
Canonical exit: 17 Apr 2024 (T+90)
8,470 shares@ US$0.391214.2% of flowCommon StockSEC:0001654954-24-000736:1
Canonical exit: 15 Apr 2024 (T+90)
7,793 shares@ US$0.386228.3% of flowCommon StockSEC:0001654954-24-000736:0
Canonical exit: 15 Apr 2024 (T+90)
709,703 shares0Common StockSEC:0001654954-23-003613:1
2,264 shares0Common StockSEC:0001654954-23-003613:2
1,779 shares0Common StockSEC:0001654954-23-003615:0
277,597 shares0Common StockSEC:0001654954-23-003613:0
2,575 shares0Common StockSEC:0001654954-23-003617:0
84 shares@ US$2.67100.0% of flowCommon StockSEC:0001654954-23-002940:0
4,241 shares@ US$0.301368.5% of flowCommon StockSEC:0001209191-22-031625:0
1,361 shares@ US$0.3013100.0% of flowCommon StockSEC:0001209191-22-031621:0
2,684 shares@ US$2.6215.1% of flowCommon StockSEC:0001209191-21-066775:1
8,149 shares@ US$2.6264.6% of flowCommon StockSEC:0001209191-21-066773:1
11,759 shares0Common StockSEC:0001209191-21-066775:0
34,752 shares0Common StockSEC:0001209191-21-066773:0
4,000 shares0Common StockSEC:0001209191-21-039047:0
4,000 shares0Common StockSEC:0001209191-21-039054:0
25 of 111 declarations
About Flyte Aviation, Inc.
Ra Medical Systems, Inc. is a U.S. medical device company that has evolved from an excimer-laser platform developer into an electrophysiology-focused business under the Catheter Precision identity. The company was founded in 2002 in California and later reincorporated in Delaware in 2018. Its public equity history has been tied to the U.S. NYSE American market under the ticker RMED, placing it in the small-cap medtech segment of the United States.
Historically, Ra Medical built its business around advanced excimer laser technology for vascular and dermatological applications. Its legacy portfolio included the DABRA laser system for peripheral artery disease and the Pharos laser for skin conditions such as psoriasis and related inflammatory dermatological diseases. Over the past several years, however, the company has undergone a major strategic transition. In 2021 it sold its dermatology business, and in 2023 it completed a merger with Catheter Precision, a privately held company focused on electrophysiology solutions. That transaction fundamentally changed the company’s operating profile and long-term strategic narrative.
Read moreShow less
Today, the company’s core focus is on products used in electrophysiology procedures and cardiac rhythm management workflows. Its main offering is VIVO, a non-invasive 3D imaging system designed to help localize the origin of idiopathic ventricular arrhythmias before EP procedures. The portfolio also includes adjunct products such as LockeT. This positions the company in a specialized medtech niche where clinical differentiation, physician adoption, and hospital workflow integration matter more than large-scale manufacturing volume.
Competitively, Ra Medical operates in a market crowded with much larger and better-capitalized device manufacturers, particularly in cardiology, mapping, and ablation-related technologies. As a result, the company’s success depends on clinical validation, regulatory execution, reimbursement dynamics, and effective commercial adoption. Its smaller scale is a disadvantage in distribution and R&D spend, but it may also allow for focused development in specific use cases that are not fully addressed by larger rivals.
Geographically, the company is based in the United States and primarily addresses the domestic market through hospitals, electrophysiology labs, and specialist physicians. Recent corporate milestones include the merger with Catheter Precision, the continued shift away from legacy laser businesses, and the commercialization ramp of VIVO and related products. For investors, RMED should be viewed as a U.S.-listed micro/small-cap medtech story with high execution risk but meaningful product-focused upside if clinical and commercial adoption continues to improve.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
